Influenza Articles
The antibody CR9114 shows promise in combating future flu pandemics as it appears to neutralize any influenza virus.
A potentially effective mucosal vaccine platform has been developed to encourage broad, protective immunity against multiple influenza virus infections.
A new study shows that influenza vaccination may help protect against heart attack and stroke even when it does not prevent people from getting the flu.
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
A new study demonstrates a way to stop the influenza virus from leaping from one host to the next while continuing to keep the virus from replicating inside the host.
A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus.
In a proof-of-concept study, researchers at Texas Tech University successfully vaccinated mice against influenza by cleaning their teeth with dental floss coated with inactive flu viruses.
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
A new clinical trial shows a single shot of a long-lasting influenza (flu) drug may protect people for an entire season, and it might do so more effectively than vaccines.
In a late-stage trial, Novavax's experimental COVID-19-influenza combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccines generated a strong immune response in adults aged 65 and older, similar to already approved vaccines against the viruses.
Scientists at Ohio State University have created an antibody that was successful in protecting a majority of the tested mice from lethal influenza (flu) doses, even preventing some from experiencing any symptoms at all.
A recent study of Moderna’s combination influenze (flu) and COVID-18 vaccine, mRNA-1083, found that it induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all four influenza strains (among those ages 50 to 64 years), the three clinically relevant influenza strains (among those aged 65 years and older), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile.